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A B S T R A C T
Cannabinoids (CB), transient receptors potential vanilloid type 1 (TRPV1) and nitric oxide (NO) were found to be
interlinked in regulating some neuronal functions such as membrane excitability and synaptic transmission.
TRPV1 play a fundamental role since it represents a synaptic target for CB that triggers several downstream
cellular pathways. In this regard, recent evidence report that TRPV1 could inﬂuence NO production by mod-
ulating neuronal NO synthase (nNOS) activity. In the present research, we pointed to manipulate nNOS function
to assess its role on TRPV1 signalling in hyperexcitability conditions elicited in the dentate gyrus of hippocampal
formation. The activation of TRPV1 receptors is achieved by administering capsaicin (CAP), the main TRPV1
agonist exerting a widely reported proepileptic eﬀects. In order to focus on nNOS activity, we used 7-ni-
troindazole (7NI), nNOS inhibitor, or L-Arginine (ARG), NO precursor, before CAP. Then, the eﬀects of each of
these co-administration protocols were tested in presence of WIN 55,212, a CB agonist. The study was conducted
in rats using an electrically-induced acute model of temporal lobe hyperexcitability, the Maximal Dentate
Activation (MDA), considering diﬀerent indicators of paroxysmal activity such as: percentage of responses to
electrical stimulation, MDA discharge parameters and threshold current intensity for MDA. Data showed that the
excitatory eﬀects of CAP were reduced by 7NI and enhanced by ARG pretreatments, respectively. In addition, the
co-treatment with WIN counteracted CAP eﬀect, substantially resulting in an inhibitory eﬀect. Finally, the CAP-
WIN functional interaction appeared to be modulated by interfering with NO signalling since 7NI increased the
inhibitory eﬀect induced by the co-treatment with CAP and WIN, whereas ARG reduced it. These ﬁndings
suggest that nNOS function could be involved in the CB/TRPV1 signalling and shed light on a new putative
cannabinoid-related control of neuronal hyperexcitability in the hippocampus
1. Introduction
Transient receptors potential vanilloid type 1 (TRPV1) have been
reported to inﬂuence neuronal excitability (Li et al., 2004; Castillo
et al., 2012; Ligresti et al., 2016). These cation channels, usually dis-
tributed in the nervous system in post-synaptic sites, are mainly known
for integrating peripheral noxious stimuli transmitted by natural va-
nilloids such as capsaicin (CAP), the main TRPV1 agonist, as well as by
heat and acids (Szallasi and Blumberg, 2007). Beyond this, a con-
tribution of TRPV1 to the pathophysiology of epileptic disorders has
been extensively addressed, since it was reported that the activation of
TRPV1 enhances excitability of neurons by increasing Na+ and Ca2+
permeability and, in turn, excitatory transmission (Li et al., 2004;
Nazıroğlu, 2015). Moreover, TRPV1 present an additional binding site
for endocannabinoids and is considered important for cannabinoid (CB)
non-retrograde regulation of neuronal conductances, especially in epi-
leptogenic areas such as the hippocampus (Cristino et al., 2006; Castillo
et al., 2012). Indeed, TRPV1 have been accounted as a possible “io-
notropic receptor counterpart” for cannabinoid metabotropic receptors
type 1 (CB1R), since many pharmacological eﬀects of cannabinoid
agonists can be modulated by TRPV1 antagonism, knockout and de-
sensitization (Szallasi and Blumberg, 2007; Ligresti et al., 2016). Fur-
thermore, several researches suggested that CAP and capsazepine, a
TRPV1 antagonist, have respectively pro- and antiepileptic properties
in seizure models (Fu et al., 2009; Gonzalez-Reyes et al., 2013; Jia et al.,
2015) and that such actions are inﬂuenced by cannabinoids through
direct binding of vanilloid receptors or by targeting common synaptic
modulators (Bhaskaran and Smith, 2010; Castillo et al., 2012; Manna
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and Umathe, 2012). In this regard, we have previously proposed that
TRPV1 activation could reduce the inhibiting action of the CB agonist
WIN 55,212 (hereafter WIN) by enhancing post-synaptic excitability
levels (Carletti et al., 2016b). Noteworthy, CB and TRPV1 signalling
were suggested to possibly share as intracellular target the neuronal
Nitric Oxide Synthase (nNOS), a calcium-dependent enzyme generating
nitric oxide (NO) from the precursor L-Arginine (ARG) (Ahern et al.,
2002). We have previously reported the eﬀects of NO-active drugs in a
model of temporal lobe hyperexcitability. In particular, the discharge
elicited in the hippocampus was limited by reducing the activity of
nNOS with 7-nitroindazole (7NI), a preferential nNOS inhibitor;
whereas, the increase in NO synthesis administering ARG, induced an
exacerbation of paroxysmal phenomena (Borowicz et al., 2000; Sardo
et al., 2008; Banach et al., 2011). Nitrergic system is involved in nu-
merous CB eﬀects on neuronal hyperexcitability (Kim et al., 2006a,b;
Bahremand et al., 2009), either by means of CB1-activated pathway or
by post-synaptic TRPV1 involvement (Jones et al., 2008, Aguiar et al.,
2014; Batista et al., 2015). Recently, we have shown that the inhibition
of nNOS by 7NI strengthened the inhibitory eﬀects of WIN (Carletti
et al., 2015). Moreover, several evidence highlighted that systemic
administration of CAP increased NO synthesis in several rat brain re-
gions, whereas capsazepine impaired NO-induced eﬀects (Okere et al.,
2000; Lisboa et al., 2013). Noticeably, lateral amygdala long-term po-
tentiation was hinted to be dependent on TRPV1, gated by CAP and
modulated by cannabinoids, with an involvement of NO-mediated
glutamatergic transmission (Zschenderlein et al., 2011). Similarly, the
activity of cannabinoids on behavioural responses appears to be related
to NO levels via modulation of TRPV1 (Aguiar et al., 2014; Batista et al.,
2015; Uliana et al., 2016). Nevertheless, the reciprocal relationships
between TRPV1/CB and nitrergic systems in the modulation of neu-
roexcitability and, in turn, paroxysmal phenomena are still elusive.
Our investigation aimed to explore possible combined eﬀects be-
tween TRPV1, CB and nNOS activity in the control of hippocampal
hyperexcitability. To serve this purpose, a pharmacological manipula-
tion of CB/TRPV1 and nitrergic systems was performed in an acute rat
in vivo model of temporal lobe hyperexcitability, the Maximal Dentate
Activation (MDA), free of chemical interferences and mimicking the
electrophysiological characteristics of epileptic discharges by triggering
the hippocampal-parahippocampal circuitry (Rizzo et al., 2014). In the
MDA, electrically-induced hyper-activation of the limbic system de-
termines synchronous burst ﬁring of cells in the dentate gyrus (DG); this
eﬀect constitutes a bio-electric marker of acute hyperexcitability in the
hippocampus, a brain area where neuronal excitability was demon-
strated to be regulated by multiple factors (Stringer and Lothman,
1989; Sardo et al., 2012; Kandel et al., 2014; Plescia et al., 2014a,b;
Allegra et al., 2015). In the present study, we took into consideration
the DG response to electric stimulation, the parameters describing MDA
ﬁring (onset, MDA and afterdischarge, see Methods) and the activation
threshold for the synchronous discharge. At ﬁrst, we evaluated the ef-
fects of manipulating nNOS activity on CAP-induced discharge by co-
administering CAP with 7NI or with ARG. Then, we also assessed if a
nitrergic-dependent modulation of paroxysmal activity could still oc-
curr when CB and TRPV1 systems are simultaneously activated by co-
administering WIN and CAP. This experimental approach, pointed at
unveiling CB-related mechanisms underpinning neuronal hyperexcit-
ability, shed light on both the role of TRPV1 channels and the mod-
ulation exerted by nitric oxide.
2. Materials and methods
2.1. Animals
Male Wistar rats (weight 240–280 g, two-three months old) were
anaesthetized with urethane (1.2 g/kg intraperitoneally, i.p.). Animals
were positioned in a stereotaxic apparatus (David Kopf Instruments,
Tujunga, CA, USA), with body temperature maintained at 37–38 °C
using a heating pad. After craniotomy, a coaxial bipolar stimulating
electrode was stereotaxically placed in the right Angular Bundle (AB:
1 mm anterior to the interaural line, 3–5 mm dorsal to it and 4.4 mm
lateral to the midline) and a glass recording electrode, ﬁlled with 1%
fast Green in 2 M NaCl, was placed in the ipsilateral Dentate Gyrus (DG:
6 mm anterior to the interaural line, 3.0 mm ventral to the cortical
surface and 1.8 mm lateral to the midline), according to Paxinos and
Watson (Paxinos and Watson, 1998). Bioelectric activity was ampliﬁed
and recorded through a low level DC pre-ampliﬁer (Grass 7B, West
Warwick, RI, USA), then processed using the SciWorks package, version
5.0 (Datawave Technologies, Longmont, CO, USA). Recording and sti-
mulating electrode positions were respectively marked through ionto-
phoretic Fast Green ejection (50 μA for 10 min) and a small electrolytic
lesion (20 mA for 10 s), then they were histologically veriﬁed. On
completion of each experiment, the animals were whole-body perfused
with normal saline, followed by 10% buﬀered formalin. The brains
were removed, post-ﬁxed in the same ﬁxative overnight and then
cryoprotected in 30% sucrose/PBS. Finally, brains were sliced in 30–50-
μm serial coronal sections and stained by using Nissl-Cresyl Violet
method. The experiments were conducted in strict accordance with the
European directive (2010/63/EU) and the institutional guidelines, au-
thorized by the Italian Ministry of Health.
2.2. Electrophysiological procedures
The MDA technique has been extensively described in previous
papers (Stringer and Lothman, 1989; Carletti et al., 2015). Brieﬂy, 10 s
trains of 20 Hz stimuli (biphasic pulses of 0.3 msec each) were given
through the AB stimulating electrode in order to obtain a paroxysmal
discharge of DG. Stimulus intensity was initially below that necessary to
elicit any response (50 μA) and then increased in 50 μA steps every
2 min until MDA occurred (“threshold intensity”). Then, a stimulus
intensity 100 μA higher than the threshold intensity was used (“test
intensity”) for following stimulations. Test stimuli were administered
every 10 min until 4 h. MDA was recorded in the DG and deﬁned by a
shift of the extracellular potential in DC-coupled recordings as well as
by the presence of bursts of population spikes of 20–40 mV.
In all animals, the ﬁrst ﬁve test stimulations (baseline period) were
used as individual control, under the condition that each animal re-
sponds to all of them with a typical and reproducible MDA response
(Fig. 1A). Once the MDA was elicited, every drug treatment (see next
paragraph) started after these control stimulations. Depending on drug
treatments, after each stimulation the eventual eﬀects were diﬀerently
characterized by changes in: a) the number of animals responding to
electrical stimulation; b) the duration of parameters characterizing
MDA response; c) the threshold intensity of electrical stimulation in
animals maintaining MDA response. In order to explore all these pos-
sibilities, we ﬁrst assessed for each treated group the percentage (%) of
responses to each AB stimulation. Furthermore, as shown in Fig. 1A,
response parameters taken into consideration were: a) time of onset
(latency) as an indicator of the susceptibility of the DG to respond to
stimulation, (b) MDA duration and (c) after discharge (AD) duration
both useful to quantify the extent of hyper-activated discharge. In de-
tail: onset time is measured from the beginning of AB stimulation to the
midpoint of the DC potential shift; MDA duration is measured from the
midpoint of the DC potential shift to the point at which the evoked
paroxysmal EEG events abruptly ceased; AD is calculated from the end
of AB stimulation to the end of the synchronous activity. Lastly, when
drug treatments were followed by 100% of MDA responses eventual
decreases in the threshold intensity of electrical stimulation were ex-
plored in order to assess if changes in DG proneness to discharge oc-
curred. Therefore, within the time-frame of drug eﬃcacy, the stimula-
tion intensity was progressively lowered (50 μA steps under the
threshold intensity every ten minutes) until the MDA response dis-
appeared; the number of animals with modiﬁed threshold intensity per
group was calculated and the related reduction of intensity were
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assessed. Reductions of only 50 μA of the threshold of stimulation were
not taken into consideration.
2.3. Drug treatment
7NI and ARG were purchased from Sigma Chemical Co. (Sigma, St.
Louis,MO, USA), whilst WIN and CAP were purchased from AbCam
(Cambridge, UK). All drugs were dissolved in the same ﬁnal vehicle
volume (ARG in saline solution; 7NI, CAP and WIN in 15% of DMSO in
saline solution, as indicated in Carletti et al., 2013). Drugs were i.p.
injected, using previously published dosages (Sardo et al., 2008;
Carletti et al., 2015, Carletti et al., 2016b): CAP 10 mg/kg, ARG 1 g/kg,
7NI 50 mg/kg, WIN 10 mg/kg. Untreated and vehicle-treated control
groups (n = 6 each) were studied up to 250 min. In each remaining
group (n = 6 each) the animals received the following treatments: a)
CAP b) 7NI-CAP c) ARG-CAP d) CAP-WIN e) 7NI-CAP-WIN f) ARG-CAP-
WIN. As previously introduced, each treatment started after ﬁve con-
secutive stable MDA responses of baseline period and all the subsequent
experimental evaluations lasted up to 150 min after last drug admin-
istration (Fig. 2). When two or more drugs were injected, due to dif-
ferent pharmacokinetic drug proﬁles, adequate time intervals were in-
terposed between administrations so as to allow coincident actions (7NI
or ARG respectively 10 min before CAP and, in case, 40 min before WIN
injection; Fig. 2). Analyses on changes of the threshold intensity were
carried out in further four groups of animals (n = 6 each) sharing the
same threshold intensity (300 μA), that were administered with ARG,
CAP, 7NI-CAP and ARG-CAP (same doses as above), respectively. Also,
related vehicle-treated groups were studied. Tests on threshold were
performed starting 60 min after the last drug treatment considering the
peak of eﬃcacy of each treatment.
2.4. Statistical analysis
The Chi-square (χ2) test was used in order to statistically analyse, at
each stimulation time point, the percentage of animals responding to
AB electrical stimulation following each drug treatment within the
same experimental group or between diﬀerent treatments. This analysis
was also applied to assess the number of animals with modiﬁed
threshold intensity per group. Whereas, the eventual related reduction
of intensity was analysed by the Student’s T-test. Furthermore, for MDA
discharge parameters (onset, MDA and AD), data from each animal
(including control animals) in each group were expressed as % diﬀer-
ence (D%)± S.D. versus the last MDA response of the baseline period,
considered as the reference value, and averaged within group for sta-
tistical comparisons using the analysis of variance (ANOVA). The time
course of response parameters was analyzed using a two-way ANOVA
followed by Bonferroni post hoc test, since the occurrence of drug-in-
duced suppression of paroxysmal response did not allow the use of a
repeated measures ANOVA. Considering the analyses between groups,
each treated group was compared to the related vehicle-treated group,
used as control. Diﬀerences were considered statistically signiﬁcant
when P was less than 0.05.
Fig. 1. (A) Representative MDA trace. Measurements of time
of onset (latency), duration of maximal dentate gyrus acti-
vation (MDA) and after discharge (AD) during and after a
stimulus train (300 μA, 20 Hz) delivered for 10 s to the an-
gular bundle (AB). (B) Time course of MDA parameters in
untreated controls. Each value represents the mean duration
of D% of baseline ± S.D.
Fig. 2. Schematic representation indicating the time
of administration of the diﬀerent drugs injected per
group. The time-line of stimulation points (interval
between stimulations = 10 min) includes the base-
line period (0–50 min) and the observation period
after treatments (from 50 up to 250 min). The
treated groups are shown as follows (from bottom to
top): CAP; CAP-WIN; 7NI (or ARG)-CAP; 7NI (or
ARG)-CAP-WIN. As for treatments, the black lines
represent the observation period, including the time
of diﬀerent drug administrations indicated by ●,
until the end of the observation indicated by ♦.
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3. Results
3.1. Untreated and vehicle-treated control groups
In untreated and vehicle-treated animals, each stimulation was
systematically followed by an epileptiform response; MDA parameters
and activation threshold intensity were not altered along observation
period (Fig. 1B).
3.2. CAP and CAP-WIN-treated groups
All CAP-treated rats exhibited MDA responses after each electrical
stimulation. Statistical analysis on MDA parameters showed signiﬁcant
diﬀerences versus baseline for both MDA and AD duration (MDA:
F(15,95) = 2.45, P = 0.0052; AD: F(15,95) = 2.36, P = 0.0072). Post hoc
analysis revealed that MDA and AD durations statistically increased
from 20th to 130th min with a maximum eﬀect at 90th min (D%=
+92.03 ± 16.17 and +133.40 ± 43.48, respectively; Fig. 3). Com-
parisons of CAP group versus controls revealed signiﬁcant main eﬀects
of treatment (Onset: F(1,150) = 81.11, P < 0.0001; MDA:
F(1,150) = 250.6, P < 0.0001; AD: F(1,150) = 173.1, P < 0.0001), but
not of stimulus time or their interaction. Post-hoc test outlined sig-
niﬁcant increases in the durations of MDA and AD versus controls (for
P < 0.05).
In experiments with co-administration of CAP and WIN, some ani-
mals did not respond to electrical stimulation in the time interval be-
tween 20th and 50th min, this result being signiﬁcant at 20th min when
only 33.33% of animals responded to AB stimulation (χ2 = 6.00,
DF = 1, P = 0.0014) (Table 1). Moreover, analysis versus baseline
values showed signiﬁcant reductions in MDA (F(18,89) = 1.75,
P = 0.046) and AD (F(18,89) = 1.85.02, P = 0.016) durations. Post hoc
tests showed that MDA decreased from 30th to 100th min, with a
maximum eﬀect at 30th min (D%=−50.32 ± 1.66) and AD reduced
from 30th to 90th min with a maximum eﬀect at 30th min (D%
=−74.93 ± 2.84; Fig. 4). Further comparisons versus CAP showed
signiﬁcant diﬀerences. In detail, analysis on the time of onset of CAP-
WIN group reveal signiﬁcant main eﬀects of treatment
(F(1,150) = 330.2, P < 0.0001), with an increase from 20th to 140th
min. No changes in stimulus time or their interaction were observed.
Whereas, signiﬁcant decreases in MDA and AD were highlighted by
signiﬁcant main eﬀects of treatment (MDA: F(1,150) = 568.4,
P < 0.0001 and AD: F(1,150) = 400.1, P < 0.0001) and interaction
(MDA: F(14,150) = 2.20, P = 0.0099 and AD: F(14,150) = 2.18,
P = 0.0107), but not of stimulus time. In particular, MDA duration
went down along the entire observation period and AD from 10th to
130th min (for P < 0.05).
3.3. Eﬀect of 7NI or ARG on % of responses and MDA parameters of rats
treated with CAP
The co-administration of 7NI and CAP did not aﬀect responsiveness
to AB stimulation with respect to controls. As for the analysis on MDA
parameters, there was no signiﬁcant change in the onset time, but a rise
in both MDA (F(15,80) = 2.75, P = 0.0018) and AD (F(15,80) = 2.79,
P = 0.0015) duration versus baseline was observed. Post hoc tests
showed that they signiﬁcantly increased, respectively, from 10th to
50th min with a maximum eﬀect at the 20th min (D%
= 47.62 ± 11.39) and from 10th to 40th min with a maximum at the
20th min (D%= 67.99 ± 16.65; Fig. 3). Further comparisons were
performed on this co-treated group versus either CAP alone or controls.
When compared to CAP alone, analysis on 7NI-CAP group for the time
of onset did not reveal signiﬁcant main eﬀects of stimulus time, treat-
ment or their interaction. Whereas, a signiﬁcant decrease in MDA was
showed for 7NI-CAP group with signiﬁcant main eﬀects of treatment
(F(1,150) = 117.7, P < 0.0001) but not of stimulus time or their in-
teraction. Similarly, in the AD durations a signiﬁcant main eﬀect
emerged for treatment (F(1,150) = 95.2, P < 0.0001) but not of sti-
mulus time or their interaction. In 7NI-CAP group Bonferroni post-hoc
test showed signiﬁcant decreases in MDA and AD durations from 60th
to 130th min vs CAP alone (for P < 0.05; Fig. 3).
When ARG and CAP were co-administered, 100% of MDA responses
Fig. 3. Eﬀects of treatments on MDA parameters, (time of onset, MDA and AD) during 15 progressive stimuli. Each value represents the mean D% ± S.D. of each treatment per stimulus
versus baseline values (■ CAP,● 7NI-CAP,▼ ARG-CAP). Within-treatment statistically signiﬁcant D% vs baseline values for P < 0.05 is indicated as: (§) for all groups, (+) for CAP and
ARG-CAP groups, (#) for 7NI-CAP and ARG-CAP groups, (*) for ARG-CAP group. Between-treatment signiﬁcance of 7NI-CAP co-treatment was indicated as (°) for P < 0.05 versus CAP
group.
Table 1
Percentage (%) of animals still responding with MDA, per stimulus, in experimental
groups showing a decreased responsiveness to stimulation.
Time of stimulus (min) CTR CAP- WIN 7NI-CAP-WIN ARG-CAP-WIN
10 100 100 67 100
20 100 33** 33** 50*
30 100 67 33** 83
40 100 67 67 100
50 100 83 67 100
60 100 100 83 100
70 100 100 83 100
80 100 100 83 100
90 100 100 100 100
100 100 100 100 100
The reported signiﬁcances are from a χ2 analysis. (*) for P < 0.05, (**) P < 0.01 versus
controls (CTR). Data regarding 10 stimulations after last drug administration are dis-
played.
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to stimulation were observed. Furthermore, a within-treatment analysis
of MDA parameters revealed a signiﬁcant reduction in the onset time
(F(15,80) = 2.010, P = 0.0244), together with an increase in both MDA
(F(15,80) = 7.57, P < 0.0001) and AD (F(15,80) = 6.93, P < 0.0001)
durations, when compared to baseline. Bonferroni post hoc test re-
vealed that time of onset went down from 30th to 150th min with a
maximum eﬀect at the 80th (D%=−32.96 ± 15.07), while MDA and
AD durations increased throughout experimental session with a max-
imum eﬀect at the 50th (D%= 127.26 ± 40.22; D%
= 192.90 ± 67.79, respectively; Fig. 3). For all parameters a stronger
excitatory eﬀect of the co-administration of ARG and CAP was evident
with respect to CAP alone (Fig. 3), though between-treatment ANOVA
did not reach statistical signiﬁcance.
3.4. Eﬀect of 7NI and ARG on % of responses and MDA parameters of rats
co-treated with CAP and WIN
In animals pre-treated with 7NI before CAP and WIN, the % of MDA
responses decreased from 10th to 80th min, such reduction reaching
signiﬁcance at both 20th and 30th (MDA responses = 33%;
χ2 = 6.000, DF = 1, P = 0.0143; Table 1). As for MDA parameters,
statistical analysis showed a signiﬁcant increase in time of onset
(F(15,63) = 1.877, P = 0.043) and a signiﬁcant decrease in MDA and AD
durations ((F(15,63) = 2.21, P = 0.0146 and (F(15,63) = 1.856,
P = 0.045, respectively). Post hoc comparisons outlined an increase in
onset at 40th and 50th min, maximal at 40th (D%= 75.59 ± 32.23),
and reductions in MDA and AD framed between the 10th and the 110th
min, with a maximum eﬀect at the 30th min (D%=−69.67 ± 5.05
and D%=−80.76 ± 11.77, respectively; Fig. 4). Furthermore, com-
parisons were performed between 7NI-CAP-WIN and CAP-WIN group,
outlining signiﬁcant main eﬀects of treatment (Onset: (F(1,150) = 71.98,
P < 0.0001; MDA: (F(1,150) = 112.4, P < 0.0001; AD:
(F(1,150) = 67.66, P < 0.0001) and stimulus time (Onset:
(F(14,150) = 2.59, P = 0.0022; MDA: (F(14,150) = 5.00, P < 0.0001;
AD: (F(14,150) = 4.18, P < 0.0001), but not of their interaction. As for
7NI-CAP-WIN group, post-hoc analysis pointed out an increase in the
time of onset, from 10th to 50th min, and reductions in the duration of
MDA at 10 th, 20th and at 40th min and of AD at 10th min with respect
to CAP-WIN group (for P < 0.05).
In the group of animals pre-treated with ARG before CAP and WIN a
reduction in the number of responding animals was observed only from
20th to 40th min, with a signiﬁcant change at 20th min (MDA re-
sponses = 50%; χ2 = 4.000, DF = 1, P = 0.0045; Table 1). Though
the time of onset seemed to increase while MDA and AD durations were
reduced, analysis on MDA parameters did not show any signiﬁcant
diﬀerence versus related baseline values (Fig. 4). Between-treatment
analysis conducted comparing ARG-CAP-WIN versus CAP-WIN groups
did not highlight any statistical diﬀerences.
Lastly, signiﬁcant diﬀerences were found when comparing 7NI-CAP-
WIN with ARG-CAP-WIN groups. ANOVA revealed signiﬁcant main
eﬀects of treatment (Onset: (F(1,150) = 57.59, P < 0.0001; MDA:
(F(1,150) = 117.9, P < 0.0001; AD: (F(1,150) = 89.08, P < 0.0001)
and stimulus time (Onset: (F(1,150) = 2.46, P = 0.0036; MDA:
(F(1,150) = 2.66, P = 0.0017), but not their interaction. Indeed, the
time of onset in 7NI-CAP-WIN group increased from 20th to 40th min
and MDA and AD durations lowered from the 10th to 40th min
(P < 0.05, Fig. 4).
3.5. Changes in threshold current intensity in groups with 100% of MDA
responses
We further evaluated eventual changes in threshold current in-
tensity for hippocampal circuitry activation in experimental groups
maintaining 100% of MDA responses to electrical stimulation (Fig. 5).
The treatment with ARG alone, previously reported as a proconvulsant
agent in the same model (Sardo et al., 2008), was also taken into
consideration for these experiments. 50% of animals in the ARG group
showed a signiﬁcant−25% decrease of threshold intensity, from 300 to
225 ± 27.39 μA (ARG vs CTR: t = 2.712, DF = 10, P = 0.0219). Si-
milarly, in the CAP group, 50% of animals showed a signiﬁcant
−33.33% reduction, from 300 to 200 ± 44.72 μA (CAP vs CTR:
t = 3.162, DF = 10, P = 0.0101). Statistical comparison between ARG
and CAP groups showed no signiﬁcant diﬀerence in the magnitude of
reduction. The co-treatment with ARG and CAP caused a clear fall in
the threshold intensity by −55.56% in all animals from 300 to
133.33 ± 40.82 μA. Between-treatments analyses revealed that ARG-
CAP treatment induced a signiﬁcant reduction in threshold intensity
with respect to either ARG or CAP groups (ARG-CAP vs CAP: t = 2.697,
DF = 10, P = 0.0224; ARG-CAP vs ARG: t = 4.568, DF = 10,
P = 0.0010). Lastly, animals in 7NI-CAP group did not show any low-
ering in the threshold intensity.
4. Discussion
Recent evidence suggested that cannabinoids, vanilloid receptors
and nitric oxide can represent a synaptic ensemble modulating neuronal
activity in several brain processes (Zschenderlein et al., 2011; Lisboa
and Guimaraes, 2012; Lisboa et al., 2013). In the context of
Fig. 4. Eﬀects of treatments on MDA parameters, (time of onset, MDA and AD) during 15 progressive stimuli. Each value represents the mean D% ± S.D. of each treatment per stimulus
versus baseline values (● CAP-WIN, ♦7NI-CAP-WIN, ARG-CAP-WIN). Within-treatment statistically signiﬁcant D% vs baseline values for P < 0.05 is indicated as: (+) for 7NI-CAP-
WIN and CAP-WIN groups, (*) for 7NI-CAP-WIN group. Between-treatment signiﬁcance of 7NI-CAP-WIN indicated as (°) versus ARG-CAP-WIN and CAP-WIN group, (■) versus CAP-WIN
group and (§) versus ARG-CAP-WIN (for P < 0.05).
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hyperexcitability phenomena, we examined the eﬀects of nNOS mod-
ulation on TRPV1 activation, with or without the co-administration of a
CB agonist, applying the Maximal Dentate Activation. This model of
acute temporal lobe hyperexcitability was already exploited as a valid
paradigm to better deﬁne the activity of antiepileptic drugs, neuro-
modulators and intracellular factors (Banach et al., 2011; Rizzo et al.,
2014; Carletti et al., 2016a). Assessment of diﬀerent MDA indicators,
such as DG responsiveness to stimulation and spreading of paroxysmal
discharge, allowed to trace an electrophysiological proﬁle of the eﬀects
induced by combined drug administration. In particular, 7NI and ARG
(nNOS inhibitor and NO precursor, respectively) were ﬁrstly used to
assess inﬂuence of nNOS function on the eﬀect induced by CAP-medi-
ated TRPV1 activation. Our data showed that the inhibition of nNOS
activity markedly attenuated CAP-dependent augmentation of syn-
chronous activity, whereas the administration of ARG potentiated it.
Furthermore, taking into consideration that TRPV1 are CB post-sy-
naptic targets, we observed that the excitatory action exerted by CAP
alone was counteracted by administering WIN, a CB agonist with re-
cognized antiepileptic eﬀects (Rizzo et al., 2009; Wallace et al., 2001).
Similarly, the eﬀect of co-treatment with CAP and WIN was found to be
modulated by diﬀerent levels of nNOS activity; in particular, 7NI
strengthened WIN action, whereas ARG impaired it. In order to explain
our results, at ﬁrst it must be obviously considered that each used
molecule is per se capable of modifying the paroxysmal activity elec-
trically induced in the MDA model, as previously shown for NO active
drugs, CB receptor agonist and TRPV1 agonist (Banach et al., 2011;
Carletti et al., 2015; Carletti et al., 2016b); therefore, what we found in
our co-administration experiments should be at least observed as a “net
eﬀect” resulting from concurrent or opposite single drug eﬀects. How-
ever, some experimental evidence suggest that, besides this inter-
pretation, a certain level of direct interaction between the involved
neurotransmitter systems can be hypothesized. Indeed, our current re-
sults are ﬁrstly in line with the fact that TRPV1 activation promotes NO
production and that some TRPV1 eﬀects on neuronal excitability could
be mediated by an increase in NO amounts (Benko et al., 2005;
Zschenderlein et al., 2011). This relation was previously shown in ei-
ther NOS or TRPV1 deﬁcient animals unable to respond to CAP, in-
dicating that modulation of NO production could constitute a major
pathway through which CAP acts at neuronal level in diﬀerent brain
areas (Okere et al., 2000; Zschenderlein et al., 2011). Accordingly, our
data hint that nitrergic system might be positioned downstream TRPV1
action, in this way exerting a synergic inﬂuence on the proneness of
hippocampal neurons to generate burst discharges. This interpretation
is sustained by the evidence that CAP alone facilitated, as well as ARG,
the genesis of epileptiform discharge by decreasing threshold current
intensity for MDA and that their co-administration was able to further
lower it. Therefore, we convey the idea that the eﬀects of TRPV1 ac-
tivation are linked to nNOS function and related NO production. The
results obtained injecting 7NI or ARG before co-administering CAP and
WIN conﬁrm the relevance of nNOS activity in the control of hippo-
campal excitability exerted by interaction of CB transmission and
TRPV1 receptors (Tahmasebi et al., 2015). Indeed, with regard to MDA
parameters, 7NI-CAP-WIN group revealed a marked reduction of hyper-
excited activity when compared with CAP-WIN group. Furthermore, as
for the % of responses after AB stimulation, 7NI was found to foster
WIN protective eﬀects, against the excitatory action of CAP; in contrast,
the administration of ARG limited the level of WIN protection against
synchronous discharge, supporting the inﬂuence of CAP on the MDA.
Besides this, considering the general duration of the eﬀect exhibited by
CAP-WIN group on the MDA responsiveness (Table 1), 7NI was found to
elongate the inhibitory eﬀect, whereas pretreatment with ARG shor-
tened it.
On the basis of these data, our study endorses the idea that NO
synthesis is involved in the excitatory eﬀects induced by TRPV1 acti-
vation. Moreover, we suggest that the conﬂicting action of CB and va-
nilloid systems on the control of paroxysmal phenomena of MDA could
be, at least in part, the result of their antagonism on the regulation of
nNOS function, as already proposed for several neuronal processes
(Zschenderlein et al., 2011; Aguiar et al., 2014; Batista et al., 2015). In
this regard, TRPV1 channels have been considered as mediators of post-
synaptic CB1 signalling by gating downstream pathways that inﬂuence
neuronal ﬁring (Castillo et al., 2012; Yang et al., 2013). For instance,
endocannabinoids were found to modulate post-synaptic TRPV1, that
target nNOS and NO production, in long-term potentiation phenomena
(Zschenderlein et al., 2011). Also, it should be noted that the produc-
tion of NO has already been directly implicated as one of the crucial CB
targets (Waksman et al., 1999; Bahremand et al., 2009) and, interest-
ingly, an inhibition of NO production following WIN administration
was reported as neuroprotective against neurotoxicity (Kim et al.,
2006a,b) Therefore, it is conceivable that both TRPV1 and CB could
inﬂuence the nNOS role in regulating hyperexcitability phenomena
induced in the DG, as hinted by our electrophysiological outcomes. In
fact, TRPV1 are thought to stimulate the activity of the enzyme,
whereas cannabinoids were found to reduce NO levels (Benko et al.,
2005; Kim et al., 2006a,b; Zschenderlein et al., 2011). Such opposite
action of CB and TRPV1 could be ascribed, to some extent, to the levels
of intracellular calcium and glutamate release (Fig. 6). In this regard, it
was reported that cannabinoids are produced on demand by post-
Fig. 5. (A) Graph showing the percentage of animals (white
bars) with a reduced activation threshold current intensity
(threshold) and related percentage of threshold intensity
variations (dashed bars) in groups with 100% of responses
after electrical stimulation. Initial stimulation for each test
was of 300 μA. Signiﬁcant changes are indicated as (*) for
P < 0.05 and (**) for P < 0.001 versus controls (CTR).
Data for 7NI-CAP group, not showing any lowering in the
threshold intensity, are not reported. (B) Illustrative MDA
traces during tests for drug-related decrease in the activation
threshold current intensity in groups with 100% responses.
Each trace is recorded from the same animal, treated with
ARG-CAP, within the same experimental session. Reduced
intensity of current is indicated on the left of each trace.
Traces are obtained from stimulations with reduction by
100 μA.
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synaptic enzymes in hyper-excited glutamatergic synapses (Marsicano
et al. 2003; Monory et al. 2006). This CB synthesis results in a decreased
release of glutamate from the presynaptic terminal with a subsequent
reduction of NMDA-dependent calcium entrance on the post synaptic
site and reduced activity of calcium-sensitive nNOS (Jones et al., 2008;
Castillo et al., 2012). In contrast, TRPV1 currents were suggested to
promote the increase in intracellular calcium with a direct impact on
nNOS activity (Szallasi and Blumberg, 2007; Xing and Li, 2007; Uliana
et al., 2016). Accordingly, some authors suggested a concurrent facil-
itating action of pre-synaptic TRPV1 function on the release of gluta-
mate and a consequent NMDA-dependent rise in calcium levels
(Zschenderlein et al., 2011). In the light of this evidence, nNOS emerges
as a possible common target of CB and TRPV1 in the context of gluta-
matergic transmission. Nevertheless, our results cannot exclude a closer
relationship between CB and vanilloid systems underlying their an-
tagonism (Fig. 6). Indeed, a speciﬁc inhibition exerted by WIN on the
TRPV1 function, by dephosphorylation processes desensitizing va-
nilloid channels, was reported in nociception (Jeske, 2006; Patwardhan
et al., 2006). Also, in rat primary sensory neurons, a CB receptor agonist
decreased TRPV1 activity, probably via reduction of protein kinase A-
dependent phosphorylation (Sántha et al., 2010). Moreover, TRPV1
desensitization, caused by an endocannabinoid analogue, was sug-
gested to be involved in neuroprotection (Veldhuis et al., 2003) and a
WIN-induced attenuation of TRPV1 depolarizing currents was
previously proposed in the MDA model (Carletti et al., 2016b). Simi-
larly, regarding the putative interaction between TRPV1 channels and
NO, previous reports highlighted direct connections that are consistent
with our data of an ARG-induced enhancement of CAP eﬀects. Indeed,
it was found that TRP family channels share a NO-sensitive gate that,
following an increase of intracellular NO, is responsible for TRPV1
activation upon nitrosylation of cysteine residues of the receptor
(Yoshida et al., 2006; Nazıroğlu, 2015). Therefore, it can be suggested
that the mutual eﬀect between vanilloid and nitrergic systems could
constitute a positive feedback circuit favouring cell depolarization and
leading, when excessive, to hyperexcitability states. On this point, a
detrimental linkage between nNOS and TRP channels recently emerged
in a study about hippocampal neurotoxicity showing that the admin-
istration of a TRP agonist increased NO amounts following activation of
nNOS (Hong et al., 2016). In this view, the CB action could play a
fundamental role to maintain a balanced control of neuronal excit-
ability reducing the eﬀects induced by interaction of vanilloid and ni-
trergic systems.
In conclusion, the present study supports the idea that nNOS activity
represents a crucial point for CB-TRPV1 control of synaptic function
and neuronal excitability in the hippocampus. Cannabinoids have al-
ready been applied to neurodegenerative diseases as pharmaceutical
tools, though their use in antiepileptic therapy as not been consolidated
yet. Drug interactions investigated in this research are pointed to shed
light on unknown mechanisms of cannibinoidergic transmission. In
particular, our results could be of great relevance in phenomena of
hyperexcitability since the alterations to membrane potential leading to
paroxysmal discharges could be due to dysfunction of neuromodulatory
systems causing, in turn, unbalanced excitatory transmission. From this
perspective, the nitrergic inﬂuence on TRPV1 eﬀects indicates a puta-
tive mechanism that could be involved in cannabinoid antiepileptic
activity. Exploring modulatory factors likely involved in CB eﬀects
could constitute the bases to develop novel pharmacological strategies
to ﬁne tune CB action within the clinical setting.
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